Novo Nordisk Stock Today (Nov 7, 2025): NVO Slips as U.S. Wegovy/Ozempic Price Cuts Take Center Stage; Medicare Coverage, FTC Scrutiny and Metsera Bid in Focus
Summary: Novo Nordisk’s U.S.-listed shares (NYSE: NVO) traded lower on Friday after the company and Eli Lilly agreed to cut U.S. prices on GLP‑1 medicines to expand access, including under Medicare. The deal introduces near‑term revenue pressure but could lift volumes over time. Investors are also watching a court decision that favored Novo in its bid for obesity biotech Metsera and closely reading this week’s Q3 update and guidance cut. Investopedia+3Reuters+3Novo Nordisk+3 At a Glance — What’s moving NVO on Nov 7, 2025 Market Action Today (Nov 7) By late morning U.S. time, NVO changed hands near $45.42, down ~2.3%